# Treatment of Liver Cirrhosis Due to Hepatitis B Virus With Fuzheng Huayu and Entecavir

> **NCT02241590** · PHASE4 · UNKNOWN · sponsor: **ShuGuang Hospital** · enrollment: 700 (estimated)

## Conditions studied

- Liver Cirrhosis Due to Hepatitis B Virus

## Interventions

- **DRUG:** Entecavir + Placebo
- **DRUG:** Entecavir + Fuzheng Huayu Tablet

## Key facts

- **NCT ID:** NCT02241590
- **Lead sponsor:** ShuGuang Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2014-09
- **Primary completion:** 2019-06
- **Final completion:** 2019-06
- **Target enrollment:** 700 (ESTIMATED)
- **Last updated:** 2018-10-15

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02241590

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02241590, "Treatment of Liver Cirrhosis Due to Hepatitis B Virus With Fuzheng Huayu and Entecavir". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT02241590. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*